PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER research hub

A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study)

This study is testing new drug combinations for advanced triple-negative breast cancer that has a specific marker called PD-L1. It aims to see if they are safe and help shrink tumours.